Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics (INDP)
NASDAQ:INDP
INDP Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
INDP Stock 12 Month Forecast
Average Price Target
$5.00
▲(900.00% Upside)
| Highest Price Target$5.00 | Average Price Target$5.00 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Maxim Group
Reiterated
03/14/25
H.C. Wainwright
$12
Buy
2300.00%
Upside
Reiterated
10/16/24
We value Indaptus based on a risk-adjusted net present value (rNPV) approach, which applies a 12% discount rate and 28.5% corporate tax rate to future cash flows. This yields a total valuation of $245M, which translates into a 12-month price objective of $12 per share, given ~21M fully-diluted shares outstanding as of end-3Q25. Risks include, but are not limited to: (1) slower-than-anticipated trial enrollment; (2) negative trial outcomes; (3) adverse regulatory decisions; (4) slower-than-projected market uptake; and (5) possible dilution risk.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Maxim Group
Reiterated
03/14/25
H.C. Wainwright
$12
Buy
2300.00%
Upside
Reiterated
10/16/24
We value Indaptus based on a risk-adjusted net present value (rNPV) approach, which applies a 12% discount rate and 28.5% corporate tax rate to future cash flows. This yields a total valuation of $245M, which translates into a 12-month price objective of $12 per share, given ~21M fully-diluted shares outstanding as of end-3Q25. Risks include, but are not limited to: (1) slower-than-anticipated trial enrollment; (2) negative trial outcomes; (3) adverse regulatory decisions; (4) slower-than-projected market uptake; and (5) possible dilution risk.
INDP Analyst Recommendation Trends
Rating
Jun 24
Aug 24
Oct 24
Nov 24
Mar 25
Strong Buy
6
5
5
4
4
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
5
5
4
4
Each month's total comprises the sum of three months' worth of ratings.
INDP Financial Forecast
INDP Stock Forecast FAQ
What is INDP’s average 12-month price target, according to analysts?
Based on analyst ratings, Indaptus Therapeutics’s 12-month average price target is $5.00.
What is INDP’s upside potential, based on the analysts’ average price target?
Indaptus Therapeutics has 900.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INDP a Buy, Sell or Hold?
Indaptus Therapeutics has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Indaptus Therapeutics’s price target?
The average price target for Indaptus Therapeutics is $5.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents 900.00% Increase from the current price of $0.5.
The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents 900.00% Increase from the current price of $0.5.
What do analysts say about Indaptus Therapeutics?
Indaptus Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of INDP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.